However, only about half of GIST with secondary resistance to imatinib has secondary mutations in c-kit or PDGFRA[31]–[33] and in many cases, the efficacy of imatinib has not depended on the pattern of c-kit or PDGFRA expression. This evidence concerns the gene KIT and gastrointestinal stromal tumor.